Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 7 days matching "australia"

ResearchPUBMEDYesterday

Genomic Therapy Matching in Rare and Refractory Cancers.

Researchers studied whether matching cancer treatments to a patient's genetic test results helps people with hard-to-treat advanced cancers live longer. They looked at data from over 1,000 Australian patients with different types of advanced solid tumors who received personalized treatment recommendations based on their tumor's genetic makeup. The study used a ranking system to organize genetic matches by how much scientific evidence supported each match, and then tracked how long patients survived.

WHY IT MATTERSIf you have a rare or treatment-resistant cancer, this research suggests that genetic testing of your tumor could help your doctor choose a therapy specifically matched to your cancer's mutations, potentially improving your survival chances.
💬 Ask your doctor
ResearchRSS4 days ago

Treatment may help maintain nutrition, prevent stunted growth in SMA kids

A new study from Australia found that children with spinal muscular atrophy (SMA) who take disease-modifying therapies — medicines approved in the last 10 years that slow down the disease — were able to maintain healthy weight and avoid stunted growth. This is important because children with SMA often have trouble eating and gaining weight. The study looked at children with SMA type 1 and type 2, the most severe forms of the disease.

WHY IT MATTERSFor families managing SMA, this research provides evidence that approved treatments may help prevent malnutrition and growth problems that commonly affect children with this condition, potentially improving long-term health outcomes beyond muscle strength alone.
💬 Ask your doctorspinal muscular atrophy type 1spinal muscular atrophy type 2
Clinical trialRSS5 days ago

Neurizon gets OK to test liquid form of ALS medication in Australia

A company called Neurizon Therapeutics has been approved to test a new liquid version of a drug called NUZ-001 in Australia. This drug is being developed to treat ALS, a disease that affects nerve cells and causes muscle weakness. The company is testing this liquid form in healthy volunteers, while a tablet version of the same drug is already being tested in a larger trial in the United States.

WHY IT MATTERSIf the liquid formulation proves safe and effective, it could offer ALS patients an easier-to-take alternative to a tablet, which may improve medication adherence for people with swallowing difficulties—a common symptom of ALS.
👁 Watch this spaceamyotrophic lateral sclerosis

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases